Demand for Evidence Supported by EBM and the Functional Food Labeling System
First written in FY2016. 8 of 30 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「Under the FOSHU system for foods with function claims, the importance of scientific evidence has increased further, as efforts are being made to improve the system's reliability through reviews of notification and operational procedures.」
EBM, the FOSHU system and healthcare DX continue to be cited as the business environment supporting demand for evidence. - FY2025AdvancedAnnual report
「Orders totaled ¥362 million, up 14.5% from the previous fiscal year, while the order backlog at the end of the consolidated fiscal year was ¥331 million, up 57.3% from the end of the previous fiscal year.」
In the evaluation testing business, orders totaled ¥362 million and the order backlog ¥331 million, with both orders and accumulated future revenue increasing. Revenue was also ¥242 million and operating profit ¥8 million, turning profitable from an operating loss in the previous fiscal year. - FY2024AdvancedAnnual report
「We recorded ¥131 million in revenue from contract fees and other income, primarily for clinical evaluation tests concerning the efficacy and safety of food products, down 46.4% from the previous fiscal year. Orders totaled ¥316 million, up 87.1%, while the order backlog at the end of the consolidated fiscal year was ¥210 million, up 429.1% from the end of the previous fiscal year.」
Revenue in the evaluation testing business declined, while orders rose substantially to ¥316 million and the order backlog to ¥210 million. Demand for evidence has materialized as accumulated future revenue. - FY2024-Q3Evaluation testing revenue declined, but orders and the order backlog increasedAnnual report
「In the evaluation testing business within the biological evaluation systems business, we recorded ¥89 million in revenue from subject recruitment fees, primarily from the subject pool, contract fees for clinical evaluation tests concerning the efficacy and safety of food products, and other income, down 41.9% year on year. Orders totaled ¥280 million, up 82.6% year on year, while the order backlog at the end of the third quarter of the current fiscal year was ¥230 million, up 77.5% from the end of the same quarter of the previous fiscal year.」
Revenue in the evaluation testing business was below the previous-year period, while orders and the order backlog increased substantially. Demand for evidence is reflected in accumulated future orders, but revenue recognition remains weak. - FY2024-Q2Revenue declined, but orders and the order backlog increasedAnnual report
「In the evaluation testing business within the biological evaluation systems business, we recorded ¥65 million in revenue from subject recruitment fees, primarily from the subject pool, contract fees for clinical evaluation tests concerning the efficacy and safety of food products, and other income, down 39.1% year on year. Orders totaled ¥218 million, up 71.9% year on year, while the order backlog at the end of the second quarter of the current fiscal year was ¥193 million, up 28.4% from the end of the same quarter of the previous fiscal year.」
Revenue in the evaluation testing business declined, while orders and the order backlog exceeded the previous-year period. Demand for evidence is reflected in new orders and accumulated future revenue, but revenue recognition remains weak. - FY2024-Q1Revenue declined and orders increased, but the order backlog decreasedAnnual report
「In the evaluation testing business within the biological evaluation systems business, we recorded ¥13 million in revenue from subject recruitment fees and other income from the Company's subject pool, down 27.3% year on year. Orders totaled ¥98 million, up 91.3% year on year, while the order backlog at the end of the first quarter of the current fiscal year was ¥124 million, down 23.7% from the end of the same quarter of the previous fiscal year.」
Revenue in the evaluation testing business declined, while orders increased. However, the order backlog was down 23.7% from the end of the same quarter of the previous fiscal year, indicating a divergence between realized revenue and new orders on one hand and accumulated future revenue on the other. - FY2023Full-year revenue from evaluation testing declined, with the decrease in the order backlog wideningAnnual report
「In the evaluation testing business within the biological evaluation systems business, we recorded ¥244 million in revenue from contract fees and other income, primarily for clinical evaluation tests concerning the efficacy and safety of food products, down 8.0% from the previous fiscal year. Orders totaled ¥169 million, down 42.0%, while the order backlog at the end of the consolidated fiscal year was ¥39 million, down 69.5% from the end of the previous fiscal year.」
Full-year revenue, orders and the order backlog in the evaluation testing business were below the previous year, and the decrease in the order backlog widened. - FY2023-Q3Revenue increased, but orders received and the order backlog declinedAnnual report
「We recorded ¥154 million in revenue from contract fees and other income, primarily for clinical evaluation tests concerning the efficacy and safety of food products, up 31.2% year on year. Orders totaled ¥153 million, down 38.9% year on year, while the order backlog at the end of the third quarter of the current fiscal year was ¥130 million, down 45.5% from the end of the same quarter of the previous fiscal year.」
Revenue in the evaluation testing business increased, while orders and the order backlog were below the previous-year period. Revenue from realized demand for evidence and the trend in future orders have diverged. - FY2023-Q2Revenue broadly flat; orders and order backlog declinedAnnual report
「In the evaluation testing business within the biological evaluation systems business, we recorded ¥107 million in revenue from contract fees and other income, primarily for clinical evaluation tests concerning the efficacy and safety of food products, up 0.5% year on year. Orders totaled ¥127 million, down 30.0% year on year, while the order backlog at the end of the second quarter of the current fiscal year was ¥150 million, down 16.3% from the end of the same quarter of the previous fiscal year.」
Revenue in the evaluation testing business increased only 0.5% year on year, while orders and the order backlog were below the previous-year period. - FY2023-Q1Evaluation testing revenue up, but orders and order backlog downAnnual report
「In the evaluation testing business within the bioevaluation systems business, the company recognized ¥18 million in revenue from contract fees and other income mainly for clinical evaluation studies concerning the efficacy of foods, up 121.5% year on year. Orders received were ¥51 million, down 49.8% year on year, and the order backlog at the end of the first quarter of the current consolidated fiscal year was ¥163 million, down 17.8% year on year.」
For demand for evidence concerning Foods with Function Claims and other products, evaluation testing revenue increased, while orders received and the order backlog were below the same period of the previous year. Recognized revenue and future order trends are moving in different directions. - FY2022-Q3RestatedAnnual report
「In Japan, as medical costs continue to rise against the backdrop of an aging society, improving the efficiency of healthcare operations and promoting preventive healthcare have become essential issues. Against this backdrop, momentum is building for EBM (Evidence-Based Medicine), or healthcare based on scientific evidence, aimed at the appropriate and efficient delivery of healthcare. As national policy measures, the government has introduced specific health checkups and specific health guidance focused on metabolic syndrome, and requires all health insurance societies and other organizations to formulate and implement Data Health Plans, which are health promotion programs based on analysis of claims and other data. In addition, regulations on the labeling of functions for foods and other products have been relaxed, and the Foods with Function Claims system has been introduced, allowing companies to label the functions of foods and other products based on scientific evidence under their own responsibility. These and other changes in the environment may provide a tailwind for the group's business.」
The company continues to describe EBM, Data Health Plans and the Foods with Function Claims system as aspects of the business environment driving demand for evidence. - FY2022-Q1Revenue sharply down, but orders received and order backlog upAnnual report
「In the evaluation testing business within the bioevaluation systems business, the company recognized ¥8 million in revenue from contract fees and other income for clinical evaluation studies mainly concerning the stress-reducing effects of devices, down 91.3% year on year. Orders received were ¥102 million, up 39.7% year on year, and the order backlog at the end of the first quarter of the current consolidated fiscal year was ¥198 million, up 60.5% year on year.」
Revenue in the evaluation testing business declined significantly, while orders received and the order backlog exceeded the same period of the previous year. Demand for evidence increased in terms of orders, but has yet to be reflected fully in recognized revenue. - FY2021-Q3RestatedAnnual report
「In Japan, as medical costs continue to rise against the backdrop of an aging society, improving the efficiency of healthcare operations and promoting preventive healthcare have become essential issues. Against this backdrop, momentum is building for EBM (Evidence-Based Medicine), or healthcare based on scientific evidence, aimed at the appropriate and efficient delivery of healthcare. As national policy measures, the government has introduced specific health checkups and specific health guidance focused on metabolic syndrome, and requires all health insurance societies and other organizations to formulate and implement Data Health Plans, which are health promotion programs based on analysis of claims and other data. In addition, regulations on the labeling of functions for foods and other products have been relaxed, and the Foods with Function Claims system has been introduced, allowing companies to label the functions of foods and other products based on scientific evidence under their own responsibility. These and other changes in the environment may provide a tailwind for the group's business.」
The company continues to describe EBM, Data Health Plans and the Foods with Function Claims system as aspects of the business environment driving demand for evidence. - FY2021-Q2Evaluation testing revenue and orders up, order backlog downAnnual report
「In the evaluation testing business within the bioevaluation systems business, the company recognized ¥149 million in revenue from contract fees and other income mainly for clinical evaluation studies concerning the efficacy of foods, up 56.2% year on year. Orders received were ¥86 million, up 78.2% year on year, while the order backlog at the end of the second quarter of the current consolidated fiscal year was ¥84 million, down 29.3% year on year.」
Revenue and orders received from clinical evaluation studies exceeded the same period of the previous year, while the order backlog declined 29.3%. Realized demand for evidence and new orders showed signs of recovery, but the accumulation of future revenue remained weak. - FY2021-Q1AdvancedAnnual report
「In the evaluation testing business within the bioevaluation systems business, the company recognized ¥97 million in revenue from contract fees and other income mainly for clinical evaluation studies concerning the efficacy of foods, up 62.5% year on year. Orders received were ¥73 million, up 492.4% year on year, and the order backlog at the end of the first quarter of the current consolidated fiscal year was ¥123 million, up 3.3% year on year.」
Revenue, orders received and the order backlog from clinical evaluation studies exceeded the same period of the previous year, and demand for evidence concerning Foods with Function Claims and other products materialized in higher orders. - FY2020Full-year evaluation testing revenue and orders downAnnual report
「The company recognized ¥116 million in revenue from contract fees and other income mainly for clinical evaluation studies concerning the efficacy of foods, down 71.3% from the previous fiscal year. Orders received were ¥97 million, down 59.4% from the previous fiscal year, and the order backlog at the end of the current consolidated fiscal year was ¥148 million, down 11.5% from the end of the previous fiscal year.」
For demand for evidence concerning Foods with Function Claims and other products, full-year revenue, orders received and the order backlog in the evaluation testing business were below the previous year. - FY2020-Q3Evaluation testing revenue and orders downAnnual report
「In the evaluation testing business within the bioevaluation systems business, the company recognized ¥97 million in revenue from contract fees and other income mainly for clinical evaluation studies concerning the efficacy of foods, down 68.9% year on year. Orders received were ¥85 million, down 40.5% year on year, and the order backlog at the end of the third quarter of the current consolidated fiscal year was ¥155 million, down 5.7% year on year.」
For demand for evidence concerning Foods with Function Claims and other products, revenue and orders received in the evaluation testing business were below the same period of the previous year, and the order backlog also declined. - FY2020-Q2RestatedAnnual report
「As part of regulatory reform under the growth strategy, the third arrow of Abenomics, regulations on the labeling of functions for foods and other products were relaxed. The Foods with Function Claims system was introduced, allowing companies to label the functions of foods and other products based on scientific evidence under their own responsibility. These and other changes in the environment may provide a tailwind for the group's business.」
The company continues to describe EBM, Data Health Plans and the Foods with Function Claims system as aspects of the business environment driving demand for evidence. - FY2020-Q1RestatedAnnual report
「As part of regulatory reform under the growth strategy, the third arrow of Abenomics, regulations on the labeling of functions for foods and other products were relaxed. The Foods with Function Claims system was introduced, allowing companies to label the functions of foods and other products based on scientific evidence under their own responsibility. These and other changes in the environment may provide a tailwind for the group's business.」
The company continues to describe EBM, Data Health Plans and the Foods with Function Claims system as aspects of the business environment driving demand for evidence. - FY2019Revenue up, orders and order backlog downAnnual report
「The company recognized ¥406 million in revenue from contract fees and other income mainly for clinical evaluation studies concerning the efficacy of foods, up 167.2% from the previous fiscal year. Orders received were ¥239 million, down 40.6% from the previous fiscal year, and the order backlog at the end of the current consolidated fiscal year was ¥167 million, down 49.9% from the end of the previous fiscal year.」
Revenue in the evaluation testing business increased significantly, while orders received and the order backlog were below the previous year. Realized demand for evidence was reflected in revenue, but new orders and the accumulation of future revenue remained weak. - FY2019-Q3Revenue up, orders downAnnual report
「In the evaluation testing business within the bioevaluation systems business, the company recognized ¥312 million in revenue from contract fees and other income mainly for clinical evaluation studies concerning the efficacy of foods, up 139.3% year on year. Orders received were ¥143 million, down 53.8% year on year, and the order backlog at the end of the third quarter of the current consolidated fiscal year was ¥165 million, down 37.4% year on year.」
Revenue in the evaluation testing business increased 139.3% year on year, while orders received fell 53.8% and the order backlog fell 37.4%. Realized demand for evidence was reflected in revenue, but new orders remained weak. - FY2019-Q2AdvancedAnnual report
「In the evaluation testing business within the bioevaluation systems business, the company recognized ¥138 million in revenue from contract fees and other income mainly for clinical evaluation studies concerning the efficacy of foods, up 130.2% year on year. Orders received were ¥99 million, down 28.5% year on year, and the order backlog at the end of the second quarter of the current consolidated fiscal year was ¥295 million, up 81.9% year on year.」
Revenue and the order backlog from clinical evaluation studies exceeded the same period of the previous year, and demand for evidence concerning Foods with Function Claims and other products materialized in a larger order backlog. Orders received, however, declined year on year. - FY2019-Q1AdvancedAnnual report
「Inquiries for clinical evaluation studies to obtain data for notifications under the Foods with Function Claims system have been increasing. Orders received were ¥63 million, up 123.8% year on year, and the order backlog at the end of the first quarter of the current consolidated fiscal year was ¥373 million, up 295.7% year on year.」
Orders received and the order backlog for clinical evaluation studies for notifications under the Foods with Function Claims system increased significantly, and demand for evidence further materialized in orders. - FY2018AdvancedAnnual report
「Orders for clinical evaluation studies for notifications under the Foods with Function Claims system continued to increase. Orders received were ¥402 million, up 108.6% from the previous fiscal year, and the order backlog at the end of the current consolidated fiscal year was ¥334 million, up 300.5% from the end of the previous fiscal year.」
Orders received and the order backlog for clinical evaluation studies for notifications under the Foods with Function Claims system increased significantly, and demand for evidence further materialized in orders. - FY2018-Q3AdvancedAnnual report
「In the evaluation testing business within the bioevaluation systems business, the company recognized ¥130 million in revenue from contract fees and other income mainly for clinical evaluation studies concerning the efficacy of foods, down 12.4% year on year. In terms of orders, contract work for clinical evaluation studies to obtain data for notifications under the Foods with Function Claims system remained strong. Orders received were ¥311 million, up 111.3% year on year, and the order backlog at the end of the third quarter of the current consolidated fiscal year was ¥263 million, up 166.3% year on year.」
Contract work for clinical evaluation studies for notifications under the Foods with Function Claims system remained strong, and orders received and the order backlog increased significantly year on year. Demand for evidence has materialized in higher orders. - FY2018-Q2RestatedAnnual report
「As part of regulatory reform under the growth strategy, the third arrow of Abenomics, regulations on the labeling of functions for foods and other products were relaxed. The Foods with Function Claims system was introduced, allowing companies to label the functions of foods and other products based on scientific evidence under their own responsibility. These and other changes in the environment may provide a tailwind for the group's business.」
The company continues to describe the Foods with Function Claims system, EBM and Data Health Plans as aspects of the business environment driving demand for evidence. - FY2018-Q1RestatedAnnual report
「As part of regulatory reform under the growth strategy, the third arrow of Abenomics, regulations on the labeling of functions for foods and other products were relaxed. The Foods with Function Claims system was introduced, allowing companies to label the functions of foods and other products based on scientific evidence under their own responsibility. These and other changes in the environment may provide a tailwind for the group's business.」
The company continues to describe EBM, Data Health Plans and the Foods with Function Claims system as aspects of the business environment driving demand for evidence. - FY2017-Q3RestatedAnnual report
「Inquiries for clinical evaluation studies to obtain data for notifications under the Foods with Function Claims system have been increasing. Orders received were ¥147 million, up 11.5% year on year, while the order backlog at the end of the third quarter of the current consolidated fiscal year was ¥99 million, down 0.4% year on year.」
Inquiries for clinical evaluation studies for notifications under the Foods with Function Claims system continued to increase, and orders received rose year on year, while the order backlog was broadly flat year on year. - FY2017-Q1AdvancedAnnual report
「Inquiries for clinical evaluation studies to obtain data for notifications under the Foods with Function Claims system have been increasing. Orders received were ¥114 million, compared with ¥3 million in the same period of the previous year, and the order backlog at the end of the first quarter of the current consolidated fiscal year was ¥196 million, up 129.3% year on year.」
Demand for evidence arising from the Foods with Function Claims system has materialized in increased inquiries for clinical evaluation studies, orders received and the order backlog. - FY2016First statedAnnual report
「Demand is increasing for the development and use of evidence, which is a strength of the group.」
The company explains that the spread of EBM, Data Health Plans and implementation of the Foods with Function Claims system are factors driving demand growth in the pharmaceutical, food, cosmetics and healthcare fields.